Abstract
Proton pump inhibitors are commonly utilized for the treatment of gastric acid-related diseases, such as gastroesophageal reflux disease, peptic ulcer disease, and Helicobacter pylori infection, and for the prevention of low-dose aspirin or nonsteroidal anti-inflammatory drug-induced peptic ulcers. Vonoprazan is a first-in-class potassium-competitive acid blocker, which has distinct advantages compared to other conventional proton pump inhibitors in terms of the efficacy for acid suppression. Due to its strong gastric acid suppression capabilities, vonoprazan serves as an effective drug for the treatment of gastroesophageal reflux disease and H. pylori infection.
| Original language | English |
|---|---|
| Pages (from-to) | 6-14 |
| Number of pages | 9 |
| Journal | Journal of Neurogastroenterology and Motility |
| Volume | 25 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2019 Jan 1 |
Keywords
- Gastroesophageal reflux
- Helicobacter pylori
- Peptic ulcer
- Potassium
- Proton pump inhibitors
ASJC Scopus subject areas
- Clinical Neurology
- Gastroenterology